EA199900861A1 - Усеченные белки, родственные фактору роста эндотелия сосудов - Google Patents

Усеченные белки, родственные фактору роста эндотелия сосудов

Info

Publication number
EA199900861A1
EA199900861A1 EA199900861A EA199900861A EA199900861A1 EA 199900861 A1 EA199900861 A1 EA 199900861A1 EA 199900861 A EA199900861 A EA 199900861A EA 199900861 A EA199900861 A EA 199900861A EA 199900861 A1 EA199900861 A1 EA 199900861A1
Authority
EA
Eurasian Patent Office
Prior art keywords
truncated
crp
proteins
growth factor
tracked
Prior art date
Application number
EA199900861A
Other languages
English (en)
Inventor
Питер Болен
Original Assignee
Коллатерал Терапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Коллатерал Терапьютикс filed Critical Коллатерал Терапьютикс
Publication of EA199900861A1 publication Critical patent/EA199900861A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение предлагает новые усеченные формы белков, родственных фактору роста сосудов эндотелия (СРБ). Указанные соединения полезны для стимуляции ангиогенеза in vitro и in vivo. Изобретение относится также к нуклеиновым кислотам, кодирующим эти новые усеченные СРБ, и к способам получения усеченных СРБ. Фармацевтические составы, содержащие усеченные СРБ, и способы генной терапии, использующие нуклеиновые кислоты, кодирующие усеченные СРБ, могут быть полезны для лечения сердечной болезни и для обработки ран.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900861A 1997-04-25 1998-04-20 Усеченные белки, родственные фактору роста эндотелия сосудов EA199900861A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
PCT/US1998/007801 WO1998049300A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Publications (1)

Publication Number Publication Date
EA199900861A1 true EA199900861A1 (ru) 2000-06-26

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900861A EA199900861A1 (ru) 1997-04-25 1998-04-20 Усеченные белки, родственные фактору роста эндотелия сосудов

Country Status (10)

Country Link
EP (1) EP0977854A2 (ru)
JP (1) JP2001524828A (ru)
KR (1) KR20010020259A (ru)
CN (2) CN1260835A (ru)
AU (1) AU7250298A (ru)
CA (1) CA2287538A1 (ru)
EA (1) EA199900861A1 (ru)
IL (1) IL132537A0 (ru)
NZ (2) NZ514872A (ru)
WO (1) WO1998049300A2 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309360T1 (de) 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
KR20010034576A (ko) * 1998-03-13 2001-04-25 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
WO1999049882A2 (en) * 1998-03-27 1999-10-07 Eicher Dorothea J Vegf and vegf-c as infant formula supplements
JP2002534058A (ja) 1998-09-08 2002-10-15 アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド 脈管内皮成長因子レセプタ一２タンパクの修飾方法およびその使用方法
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
JP4769929B2 (ja) * 1998-10-26 2011-09-07 ベジェニクス ピーティーワイ リミテッド Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
ATE406907T1 (de) 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2001057181A2 (en) * 2000-02-04 2001-08-09 Carmeliet, Peter Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
EP1323736A4 (en) * 2000-08-10 2005-08-24 Masabumi Shibuya CHIMERIC GROWTH FACTOR OF HUMAN TYPE VASCULAR ENDOTHELIAL CELLS
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP2005505510A (ja) 2001-06-20 2005-02-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｖｅｇｆ−ｂによる血管新生の刺激
UA75980C2 (en) 2001-10-15 2006-06-15 Janssen Pharmaceutica Nv Substituted 4-pheny1-4-[1h-imidazol-2-yl] piperidine derivative for reducing ischaemic damages
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20120141424A1 (en) * 2009-01-07 2012-06-07 Vegenics Pty Limited Materials and Methods for the Treatment of Hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
ATE212665T1 (de) * 1992-11-18 2002-02-15 Arch Dev Corp Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
CN1194090C (zh) * 1995-03-02 2005-03-23 阿穆拉德业务有限公司 一种新的生长因子和编码这种生长因子的基因序列
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Also Published As

Publication number Publication date
WO1998049300A3 (en) 1999-03-11
AU7250298A (en) 1998-11-24
CA2287538A1 (en) 1998-11-05
CN1260835A (zh) 2000-07-19
JP2001524828A (ja) 2001-12-04
IL132537A0 (en) 2001-03-19
EP0977854A2 (en) 2000-02-09
WO1998049300A2 (en) 1998-11-05
CN1680442A (zh) 2005-10-12
NZ500530A (en) 2001-12-21
KR20010020259A (ko) 2001-03-15
NZ514872A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
EA199900861A1 (ru) Усеченные белки, родственные фактору роста эндотелия сосудов
RU95115239A (ru) Аналог эритропоэтина
AU1922101A (en) Human fgf-21 gene and gene expression products
EA200300845A1 (ru) Модифицированные антитела и способы применения
ATE83374T1 (de) Neue galenische form von fenofibrat.
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
FI885543A0 (fi) Dna-segment, polypeptider och anti-kroppar anslutande till human vaevnadsfaktor.
DE3788961D1 (de) Verfahren zur herstellung von polysubstituierten diethylentriaminpentaessigsäuren.
ATE469654T1 (de) Verwendung des erythropoietins zur regeneration von lebergewebe
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DK0473724T3 (da) Et humant cytokin, interleukin-9
EP1140971A4 (en) ANTISENS MODULATION OF NEW ANTI-APOPTOTIC BCL-2-LIKE PROTEINS
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE3268915D1 (en) Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
RU94046426A (ru) Фармацевтические композиции, способы лечения лейкоза, способ повышения уровней стволовых клеток, антагонист с - kit - лиганда, антисмысловая нуклеиновая кислота, способ лечения меланомы, способ усиления трансфекции, способ переноса гена, способ увеличения уровней периферической крови, способ повышения уровней тромбоцитов, способы модификации биологической функции, способ лечения анемии, способ улучшения приживления костного мозга, способ ускорения восстановления костного мозга, способ лечения лейкопении
ATE363293T1 (de) Injektion von autologem knochenmark in den herzmuskel
EP0061141A3 (en) Chemokinesins and chemotaxins of leukocytes and inflamed tissues: natural mediator proteins for reversible promotion of random and directional locomotion (chemokinesis and chemotaxis) for accumulation of specific leukocyte types, process of their biotechnical preparation and pharmaceutical compositions
EA200200533A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo
FI103577B1 (fi) Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamiseksi
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста